New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
07:36 EDTGERN, BTXBioTime signs definitive agreement with Geron regarding stem cell assets
BioTime (BTX) and its recently formed subsidiary BioTime Acquisition Corporation announced that they have entered into a definitive Asset Contribution Agreement with Geron Corporation (GERN) to acquire the intellectual property, including patents and patent applications, and other assets related to Geronís human embryonic stem cell programs consistent with the financial terms outlined in the letter of intent announced on November 15, 2012. Under the definitive agreement, Geron will contribute to BAC intellectual property, certain cell lines and other assets, including the Phase 1 clinical trial of hES cell-derived oligodendrocytes in patients with acute spinal cord injury, and Geronís autologous cellular immunotherapy program. BioTime will contribute to BAC $5M in cash, 8,902,077 BioTime common shares to be held by BAC, five-year warrants to purchase 8,000,000 common shares of BioTime at a price of $5.00 per share, rights to use certain clinical grade hES cell lines, a sublicense to use certain patents for stem cell differentiation technology, and minority stakes in two of BioTimeís subsidiaries, OrthoCyte Corporation and Cell Cure Neurosciences Ltd. BAC will also pay to Geron royalties on the sale of products that are commercialized, if any, in reliance upon Geron patents contributed or licensed to BAC. A private investor has also agreed to provide an equity investment of $5M in BAC and a $5M equity investment in BioTime in conjunction with the transaction. The transaction is expected to close no later than September 30.
News For BTX;GERN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 16, 2014
09:16 EDTGERNOn The Fly: Pre-market Movers
Subscribe for More Information
07:20 EDTGERNGeron announces early HSR clearance for collaboration with Janssen
Subscribe for More Information
December 15, 2014
12:01 EDTBTXBioTime unit, GE Healthcare sign set of license agreements, terms not disclosed
BioTime (BTX) announced that its subsidiary ES Cell International Pte. Ltd. and GE Healthcare (GE) have signed a set of license agreements through which GEHC received rights to ESIís stem cell patents and ESI received rights to stem cell patents controlled by GEHC, in both cases for the development of cellular assays and models derived from stem cells for use in drug discovery and toxicity screening. In addition, the agreements give GEHC the right to grant sub-licenses to the ESI patent portfolio and, in certain circumstances, ESI may further sublicense its rights for the purpose of marketing stem cell-derived products. Financial terms were not disclosed.
11:01 EDTBTXBioTime completes initial enrollment of urine-based bladder cancer test trial
BioTime and its subsidiary OncoCyte Corporation announced that OncoCyte has completed enrollment in the initial clinical study of its urine-based bladder cancer diagnostic test. The study, which involved 100 patients, was conducted in collaboration with investigators in the Department of Pathology, Division of Cytopathology, at a leading medical institution with an international reputation for excellence and discovery. Initial results of the study have been submitted for presentation at a large upcoming cancer society meeting; eventual publication of the final results in a peer-reviewed clinical journal is also anticipated. The goal of this clinical study was to assess the performance of OncoCyteís proprietary diagnostic technology in detecting the most common type of bladder cancer; namely, urothelial carcinoma. The ability of the markers tested in the studies to determine the absence, presence, or progression of UC in patients will determine the specific nature of the bladder cancer test to be developed and the regulatory approval pathway that OncoCyte will pursue.
December 12, 2014
14:52 EDTBTXBioTime to host investor and analyst meeting
Subscribe for More Information
December 8, 2014
08:11 EDTGERNGeron to host analyst and investor meeting
Subscribe for More Information
December 5, 2014
06:23 EDTGERNGeron volatility flat into American Society Hematology Annual Meeting
Geron December call option implied volatility is at 106, January is at 115, March is at 104; compared to its 26-week average of 106 according to Track Data, suggesting non-directional price movement into 56th American Society Hematology Annual Meeting abstract presentations.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use